WCN26-3683 Caplacizumab Is Effective in Achieving Early Platelet Recovery and Maintaining Stability in Immune-Mediated Thrombotic Thrombocytopenic Purpura with Post–Plasma Exchange Rebound of Anti-ADAMTS13 Antibodies: Case Series

Read full text Summarise with VIRAT
Authors: Satoru Kurihara, Takaya Handa, Masashi Nishikubo, Seinosuke Horikawa, Naoya Kamae, Fu Takata, Keisuke Osaki, Yoshimitsu Shimomura, Ryusuke Yamamoto, Yuya Nagai, Nobuhiro Hiramoto, Noboru Yonetani
+2 more Tadakazu Kondo, Akihiro Yoshimoto
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Caplacizumab, an anti–von Willebrand factor nanobody, has been shown to accelerate platelet count recovery and shorten plasma exchange (PE) and hospitalization in phase 2 and 3 trials of immune-mediated thrombotic thrombocytopenic purpura (iTTP) (N Engl J Med 2016;374:511–22; N Engl J Med 2019;380:335–46). However, real-world longitudinal data on ADAMTS13 activity and anti-ADAMTS13 antibody (inhibitor) titers during and after PE remain limited. We investigated clinical courses and laboratory profiles—including platelet count, ADAMTS13 activity, and inhibitor titers—in iTTP patients treated with PE and caplacizumab at our institution.

Fields of Study & Subjects

Complement system in diseases Platelet Disorders and Treatments Blood transfusion and management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105672–105672
Publication date
25 March 2026
Language
EN